List view / Grid view
As deeper understanding of disease makes the development and commercialisation of oncology drugs more complex, developers are under more pressure than ever to deliver value-based treatments. In this article, Rebecca Goldstein, Senior Principal, Strategic Consulting at Envision Pharma Group, explores anchoring a programme to patient experience as a solution.
The new technique could be adapted to produce a wide range of antibodies to combat chronic conditions like HIV.
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
Researchers discovered two potential new drug applications with the possible clinical use of surfactant early in COVID-19 cases.
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
Targeted alpha therapy shows promising preclinical results, increasing survival rate by 36.4 percent in recurrent tumours.
Recently there has been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the second of a three-part series, Dr Raminderpal Singh presents an example of usage of ChatGPT, which demonstrates how accessible LLMs have become for lab scientists.
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
The development of a new membrane which better mimics human extracellular membranes will enable more accurate disease research.
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
Following direct exposure of human CNS tissues to CWD prions, a significant resistance to the propagation of infection was found.
